Cymab ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  11.5% 12.4% 13.2% 15.7% 19.2%  
Credit score (0-100)  22 19 16 11 6  
Credit rating  BB BB BB BB B  
Credit limit (kDKK)  -0.0 -0.0 -0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  -2,422 -1,077 -567 -1,167 -1,206  
EBITDA  -2,422 -1,077 -733 -1,909 -3,175  
EBIT  -2,424 -1,080 -736 -1,912 -3,178  
Pre-tax profit (PTP)  -2,630.0 -1,244.5 -915.1 -2,141.8 -3,514.9  
Net earnings  -2,053.5 -955.8 -942.5 -1,541.2 -2,580.8  
Pre-tax profit without non-rec. items  -2,630 -1,244 -915 -2,142 -3,515  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  12.7 9.9 7.0 4.1 1.2  
Shareholders equity total  -2,004 -2,959 -3,902 -5,443 -8,024  
Interest-bearing liabilities  5,100 3,112 4,169 9,444 9,625  
Balance sheet total (assets)  3,492 343 383 5,166 5,556  

Net Debt  2,203 3,107 3,929 5,319 9,436  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -2,422 -1,077 -567 -1,167 -1,206  
Gross profit growth  0.0% 55.5% 47.4% -106.0% -3.3%  
Employees  0 0 1 2 2  
Employee growth %  0.0% 0.0% 0.0% 100.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  3,492 343 383 5,166 5,556  
Balance sheet change%  0.0% -90.2% 11.7% 1,250.0% 7.5%  
Added value  -2,421.9 -1,077.3 -732.8 -1,909.2 -3,174.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  11 -6 -6 -6 -6  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 -2.0 -3.0 -4.0 -5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.1% 100.3% 129.8% 163.8% 263.5%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -44.1% -24.6% -19.4% -25.7% -26.1%  
ROI %  -47.5% -26.3% -20.2% -28.1% -33.1%  
ROE %  -58.8% -49.9% -259.9% -55.6% -48.1%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  -36.5% -89.6% -91.1% -51.3% -59.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -91.0% -288.4% -536.2% -278.6% -297.2%  
Gearing %  -254.6% -105.2% -106.8% -173.5% -120.0%  
Net interest  0 0 0 0 0  
Financing costs %  8.1% 4.0% 4.9% 3.4% 3.8%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.6 0.1 0.1 4.4 3.6  
Current Ratio  0.6 0.1 0.1 4.4 3.6  
Cash and cash equivalent  2,897.4 5.5 239.3 4,124.8 188.2  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  21.3 0.0 37.9 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -2,020.3 -2,973.7 -3,913.3 3,996.0 3,996.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 -733 -955 -1,587  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 -733 -955 -1,587  
EBIT / employee  0 0 -736 -956 -1,589  
Net earnings / employee  0 0 -943 -771 -1,290